Candace B. Johnson, Donna Walther, Matthew J. Baggott, Lisa E. Baker, Michael H. Baumann
5 min
MDMA is a promising adjunct for PTSD treatment but carries significant risks, including cardiovascular strain and potential neurotoxicity. Researchers are seeking safer, MDMA-like compounds that retain therapeutic efficacy. This study investigates whether novel benzofuran derivatives—specifically the enantiomers of 5-(2-methylaminobutyl)benzofuran (5-MABB) and 6-(2-methylaminobutyl)benzofuran (6-MABB)—can serve as viable alternatives by acting as monoamine releasers.
The researchers employed a two-pronged methodology. First, they used in vitro transporter assays in rat brain synaptosomes to determine how these compounds interact with the serotonin (SERT), norepinephrine (NET), and dopamine (DAT) transporters. They measured both uptake inhibition and the ability of the drugs to induce neurotransmitter release. Second, they used in vivo drug discrimination tests in male rats trained to identify MDMA versus saline to see if the benzofuran derivatives could produce similar interoceptive effects.
The study found that the S-isomers of 5- and 6-MABB are efficacious releasers across all three monoamine transporters (SERT, NET, and DAT), mirroring the mechanism of MDMA. In contrast, the R-isomers exhibit a hybrid profile: they are potent releasers at SERT but show significantly reduced or absent releasing activity at DAT and NET. In behavioral tests, all tested compounds successfully substituted for MDMA, with the S-isomers demonstrating higher potency than the R-isomers. This suggests that the aminoalkyl benzofuran scaffold is a promising template for developing therapeutic agents with MDMA-like properties.
By identifying compounds that share MDMA's pharmacological profile but potentially offer different metabolic or safety characteristics, this research advances the search for next-generation entactogens. The ability to fine-tune transporter activity—such as reducing DAT-mediated release—may lead to medications that provide the therapeutic benefits of MDMA while minimizing the risks of abuse or adverse cardiovascular side effects.
Alex: Though full substitution in a discrimination assay tells you the stimulus is similar, not that the mechanism is identical. There could still be residual DAT or NET activity carrying some of that signal.
Sam: That's a fair challenge, and the authors are careful about it. The R-isomers are partial releasers at the norepinephrine transporter — not silent there, just attenuated. So you can't cleanly attribute the discrimination result to SERT alone. Disentangling the relative contributions of serotonin versus norepinephrine in that behavioral response would require selective antagonist work that this study doesn't include. That's the experiment that would really close the argument.
Alex: There's also a pharmacokinetic angle here. MDMA's metabolic profile is part of what makes it clinically awkward.
Sam: Right. MDMA inhibits CYP2D6, which is also the primary enzyme responsible for its own metabolism. That creates a nonlinear pharmacokinetic profile — as plasma levels rise, clearance slows, and the drug accumulates in ways that are difficult to predict. The benzofuran derivatives are being evaluated partly to see whether they sidestep that bottleneck. If they do, you'd get a more predictable dose-response relationship, which matters enormously in a therapeutic context where you're trying to titrate an experience.
Alex: Is there evidence they actually avoid that metabolic issue, or is that still speculative?
Sam: Still largely speculative at this stage. The paper characterizes the transporter pharmacology in detail, but the in vivo metabolic data isn't fully resolved. That's another gap where the translational picture is incomplete.
Alex: And what about the generalizability of the animal model itself?
Sam: That's the limitation I'd flag most prominently. The study uses male Sprague-Dawley rats exclusively. Sex-based differences in monoamine transporter expression and CYP enzyme activity are well-documented, and they could meaningfully shift both the effective dose and the selectivity profile in females. The therapeutic index that looks clean in this model might not hold across sexes. Any path toward clinical translation would need to address that directly.
Alex: So where does this leave the field? Meaningful step forward, or still early scaffolding?
Sam: It's a credible proof of concept with real constraints. The core finding — that stereochemical modification can shift a compound from broad-spectrum to SERT-selective while preserving the entactogenic stimulus — is a useful design principle. But the mechanistic attribution is incomplete, the metabolic profile needs more work, and the animal model has obvious limitations. The follow-up experiments that would actually validate the therapeutic hypothesis — selective antagonists, female subjects, in vivo pharmacokinetics — aren't in this paper. What's here is a well-characterized starting point, not a finished argument.
Alex: The chemistry is doing something real. The question is whether the behavioral and clinical story holds up as the model gets more demanding. Thanks for walking through it, Sam.
Sam: Thanks for having me.
Alex: And thanks for listening to ResearchPod.